Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: results of double-blind and open-label cross-over trials of insulin lispro and insulin aspart

What Was Tested

Researchers studied Insulin Aspart and Insulin Lispro in this randomized controlled trial publication.

The objective of the current study was to assess mean self-monitored blood glucose (SMBG), on day 6 of 6 days of continuous reservoir wear (6D), with insulin lispro (Lis) or insulin aspart (Asp).

Who Took Part

By PubMed's age tags, the people studied were adults, both men and women.

Study 1 had an open-label, six-sequence, three-treatment, three-period, cross-over design.

Study 2 had a double-blind, two-sequence, two-treatment, two-period, cross-over design.

How the Study Was Run

In design terms this was a randomized, double-blind, open-label and crossover study.

The participants were allocated by chance, so the Insulin Aspart group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Insulin Aspart, so expectations could not easily colour the readings.

Being open-label, the Insulin Aspart study did not mask who received what.

Each person switched between Insulin Aspart and the comparison at some point, usually with a gap in between.

Safety measures were also assessed.

What Was Measured

The subject headings attached to it are Blood Glucose, Blood Glucose Self-Monitoring, China, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Hyperglycemia and Hypoglycemia.

The authors tagged it with the keywords insulin aspart, insulin infusion, insulin lispro and 关键词：门冬胰岛素，胰岛素输注，赖脯胰岛素，1型糖尿病.

What This Means in Plain Language

The paper is a randomized, double-blind and open-label study of Insulin Aspart and Insulin Lispro.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2015 (Journal of diabetes), a journal based in Australia.

More context: the Insulin Aspart compound page and the Insulin Lispro compound page, all human trials.